Related Experiment Video
Updated: Jun 23, 2026
06:06
Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones
Published on: February 5, 2018
Dextromethorphan hydrobromide preparations on the Belgian market--a comparative study.
1Service de Contrôle des Médicaments APB, rue Stevin 137, B-1000 Bruxelles.
Journal De Pharmacie De Belgique
|April 28, 2009
Summary
Oral liquid formulations containing dextromethorphan hydrobromide were tested for quality. All products met the required standards for identity, content, and microbiological safety, ensuring patient safety.
Area of Science:
- Pharmaceutical Sciences
- Quality Control
- Microbiology
Background:
- Dextromethorphan hydrobromide is a common antitussive agent found in many oral liquid preparations.
- Ensuring the quality of pharmaceutical products is crucial for patient safety and therapeutic efficacy.
Purpose of the Study:
- To verify the identity, content, and microbiological quality of oral liquid preparations containing dextromethorphan hydrobromide.
- To confirm that the pharmaceutical products meet established quality standards.
Main Methods:
- Utilized a previously validated assay method for quantitative analysis.
- Performed identity testing, content uniformity analysis, and microbiological quality assessments.
- Adhered to international guidelines for pharmaceutical testing and validation.
Main Results:
- All tested liquid preparations containing dextromethorphan hydrobromide passed the identity verification.
- The content of dextromethorphan hydrobromide in all samples was within the acceptable range.
- Microbiological quality testing confirmed that all products were free from harmful microbial contamination.
Conclusions:
- The examined liquid preparations containing dextromethorphan hydrobromide comply with all postulated quality requirements.
- The validated assay method provides reliable results for quality control of these formulations.
- The findings support the safety and quality of the tested dextromethorphan hydrobromide oral solutions.
Related Concept Videos
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:28Adrenergic Agonists: Mixed-Action Agents
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
01:14Drug Dissolution: Requirements and Profile Comparison
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...